Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunisation against hepatitis B in man.

P Maupas, A Goudeau, P Coursaget

    Lancet (London, England)
    |June 26, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Human papillomavirus (HPV) vaccines].

    Virologie (Montrouge, France)·2021
    Same author

    [Early resistance to adefovir during treatment of a chronic hepatitis B].

    Virologie (Montrouge, France)·2021
    Same author

    [The genetic diversity of hepatitis C virus and its implications for pathogenesis and resistance to treatment].

    Virologie (Montrouge, France)·2021
    Same author

    Fatal outcome after reactivation of inherited chromosomally integrated HHV-6A (iciHHV-6A) transmitted through liver transplantation.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
    Same author

    Detection of Bartonella in cat scratch disease using a single-step PCR assay kit.

    Journal of medical microbiology·2017
    Same author

    Impact on the medical decision-making process of multiplex PCR assay for respiratory pathogens.

    Epidemiology and infection·2017
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    Same journal

    Dual mobility total hip replacement in fractures: stability promotes patient confidence.

    Lancet (London, England)·2026
    Same journal

    Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

    Lancet (London, England)·2026
    See all related articles

    An inactivated hepatitis B vaccine, derived from purified HBs antigen, demonstrated safety and efficacy in chimpanzees and humans. This vaccine successfully protected individuals in a haemodialysis unit, indicating its protective potential against hepatitis B virus.

    Area of Science:

    • Hepatology
    • Vaccinology
    • Immunology

    Background:

    • Hepatitis B virus (HBV) poses a significant global health risk, particularly in healthcare settings like haemodialysis units.
    • Effective vaccines are crucial for preventing HBV infection and its chronic sequelae.
    • Development of safe and immunogenic HBV vaccines is an ongoing area of research.

    Purpose of the Study:

    • To prepare and evaluate an inactivated vaccine against hepatitis B using purified HBs antigen.
    • To assess the safety and efficacy of this vaccine in animal models (chimpanzees) and human subjects.
    • To determine the vaccine's protective effect in a high-risk population (haemodialysis unit patients and staff).

    Main Methods:

    • Preparation of an inactivated vaccine from purified hepatitis B surface antigen (HBsAg) using immunoadsorbent chromatography.

    Related Experiment Videos

  • Pre-clinical safety and efficacy testing in chimpanzees.
  • Clinical trial involving vaccination of patients and staff in a haemodialysis unit.
  • Assessment of vaccine efficacy through monitoring humoral and cellular immune responses and HBs antigenaemia levels.

    • Main Results:

    • The inactivated hepatitis B vaccine was successfully prepared and demonstrated safety in chimpanzees.
    • Vaccination in chimpanzees showed protective efficacy against hepatitis B.
    • In the haemodialysis unit, the vaccine elicited immune responses and reduced HBs antigenaemia in vaccinated subjects.
    • The vaccine provided protection against hepatitis B in the studied high-risk population.

    Conclusions:

    • The developed inactivated hepatitis B vaccine is safe and effective.
    • The vaccine successfully protects against hepatitis B infection, particularly in high-risk environments.
    • This vaccine represents a viable strategy for hepatitis B prevention in vulnerable populations.